Abstract
Almost a year after the COVID-19 pandemic had begun, The United Kingdom, South Africa, and Brazil became the epicenter of new lineages, the Variant of Concern (VOCs), B.1.1.7, B.1.351, and P.1, respectively. These VOCs are increasingly associated with enhanced transmissibility, immunity evasion, and mortality. The previous most prevalent lineages in the state of Rio Grande do South (Brazil), B.1.1.28 and B.1.1.33 were rapidly replaced by P.1 and P.2, two B.1.1.28-derived lineages harboring the E484K mutation. To perform a genomic characterization of SARS-CoV-2 samples from COVID-19 patients from the metropolitan region of Porto Alegre (Rio Grande do Sul, Southern Brazil), in this second pandemic wave, we sequenced viral samples from patients of this region to: (i) identify the prevalence of SARS-CoV-2 lineages in the region, the state and bordering countries/states, (ii) characterize the mutation spectra, and (iii) hypothesize possible viral dispersal routes by using phylogenetic and phylogeographic approaches. As results, we not only confirmed that 96.4% of the samples belonged to the P.1 lineage but also that approximately 20% of which could be assigned as the newer P.1.2 (a P.1 derived new sublineage harboring new signature substitutions recently described and present in other Brazilian states and foreign countries). Moreover, P.1 sequences from this study were allocated in several distinct branches (four clades and five clusters) of the P.1 phylogeny, suggesting multiple introductions of P.1 in Rio Grande do Sul still in 2020 and placing this state as a potential core of diffusion and emergence of P.1-derived clades. It is still uncertain if the emergence of P.1.2 and other P.1 clades are related to further virological, clinical, or epidemiological consequences. However, the clear signs of viral molecular diversification from recently introduced P.1 warrant further genomic surveillance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by donations from Florense Brands, Beppler & Puppi Advogados, Smellbox Produtos de Higiene Ltda., and Dr. Leonardo Mestre Negri. Scholarships and Fellowships were supplied by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001 and Universidade Federal de Ciencias da Saude de Porto Alegre (UFCSPA). The funders had no role in the study design, data generation and analysis, decision to publish or the preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Brazilian's National Ethics Committee (Comissao Nacional de Etica em Pesquisa - CONEP) under process number CAAE 41909121.0.0000.5553 and Comite de Etica em Pesquisa em Seres Humanos da Universidade Federal de Ciencias da Saude de Porto Alegre (CEP - UFCSPA) under process number CAAE 35083220.2.0000.5345. The study was performed in accordance with the Declaration of Helsinki. Patients included in the clinical trial approved by CONEP were informed in detail about the study and gave written informed consent to participate. Samples were anonymized before being received by the study investigators, following Brazilian and international ethical standards.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
* R.A. Zimerman and C.E. Thompson are both responsible for the work coordination, the order of senior authorship being arbitrary.
Data Availability
Full tables acknowledging the authors and corresponding labs submitting sequencing data used in this study can be found in Supplementary Files 3 and 4. Consensus genomes generated in this study were deposited in the GISAID database under Accession IDs: EPI_ISL_2139494 to EPI_ISL_2139549. Additional information used and/or analysed during the current study are available from the corresponding author on reasonable request.
